Figure S2: Probability of significant relationship between pazopanib's exposure/Ctrough and treatment outcomes/toxicity in mRCC and STS patients

The population proportion (mean and a 95% credible interval) of patients from studies in which a significant relationship between pazopanib exposure and treatment outcomes/toxicity was proven. The data were modelled as from binomial distribution under a Bayesian paradigm using an R package brms (Bürkner P (2017). “brms: An R Package for Bayesian Multilevel Models Using Stan.” Journal of Statistical Software, 80(1), 1–28. doi:10.18637/jss.v080.i01.) and weakly informative priors.

Original dataset: Sum of the patients from the studies (STS=6, RCC=7) regarding the relationship between pazopanib Ctrough/exposure and treatment outcomes/toxicity: